Advanced Enzyme to buy 70% stake in JC Biotech

G Naga Sridhar Hyderabad | Updated on January 16, 2018

Advanced Enzyme Technologies Ltd has entered into definitive agreements with API maker JC Biotech to acquire 70 per cent stake for a consideration of Rs 50 crore.

The proposed transaction was approved by the Advanced Enzymes board on Friday.

C L. Rathi, Managing Director, Advanced Enzymes, said, “We expect this deal to immediately strengthen our market leadership in API serratiopeptidase, giving us significant competitive advantage as well as flexibility in production."

"JC Biotech has the ability to handle solvent-based fermentation and recovery, which is highly complementary to our current production process,'' he added.

Headquartered in Hyderabad, JC Biotech is the manufacturer of API serratiopeptidase, an anti-inflammatory enzyme, and has a R&D pipeline of biopharma molecules.

It also has a fairly advanced technology for the manufacturing of algal DHA, an Omega 3 Fatty Acid, which finds great application in human nutrition.

JC Biotech has a production facility in Andhra Pradesh, and has the ability to expand its fermentation capacity further.

JC Biotech currently commands a 50 per cent share in the Indian market, thereby taking Advanced Enzymes’ combined market share to 80 per cent post acquisition.

As of March 2016, JC Biotech’s revenues stood at Rs 39 crore with a profit after tax (PAT) of Rs. 2.5 crore.

The acquisition is expected to close latest by the end of December 2016.

Published on October 28, 2016

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like